Pulmonx is a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema. It develops the Zephyr Endobronchial Valve, a minimally invasive treatment for chronic obstructive pulmonary disease (COPD). The company also offers the Chartis Pulmonary Assessment system (Chartis System) and the StratX Lung Analysis platform (StratX Platform).